Announcements Trials
Browse Landscape

Phase

Phase 3 9Phase 1 4Phase 2 3Phase 1/2 2

Status

Active not recruiting 7Completed 3Recruiting 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Rectal Neoplasms 1Endometrial Adenocarcinoma 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × PF-05280014 × Clear all
NCT02654119 2026-03-23

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

University of Nebraska

Phase 2 Completed
20 enrolled 12 charts
Breast

Breast Neoplasms

NCT03365882 2026-02-10

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

SWOG Cancer Research Network

Phase 2 Completed
240 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00006089 2019-07-31

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
34 enrolled
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡